Project Grant R21CA294042
Award Date
6/5/25
Completion Date
5/31/27
Dollars Obligated
$432K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $645,873 to The University of Texas M.D. Anderson Cancer Center to develop a novel approach for producing chimeric antigen receptor (CAR) macrophages in vivo using mRNA-loaded extracellular vesicles. The goal is to evaluate the feasibility and antitumor efficacy of this approach against glioblastoma, the most common and lethal primary central nervous system cancer in adults. The...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) totaling $451,996 aims to develop a high-throughput screening platform to identify and validate novel drug therapies targeting migrating and treatment-resistant glioblastoma (GBM) cancer cells. The key products and services to be delivered include: Employing an ex vivo integrated high-throughput platform for quantitative cellular/molecular analysis and biophysical assessment of...
The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 "Cancer Treatment Research" to the University of Texas Health Science Center at Houston. The $406,611 grant, awarded on April 1, 2025, will fund research to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the function and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $695,004 to The University of Texas MD Anderson Cancer Center to conduct research aimed at improving treatment approaches for HER2-mutant non-small cell lung cancer and other HER2-mutant cancers. The key objectives are to: 1) comprehensively characterize the landscape of HER2 mutations associated with response or resistance to HER2-targeted tyrosine kinase inhibitors and...
The University of Texas MD Anderson Cancer Center received a $648,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop CAR T-cell therapy targeting CD94 in T/NK cell malignancies. The award period runs from September 1, 2023 to August 31, 2025. MD Anderson is a comprehensive cancer treatment and research center that has extensive experience conducting federally funded biomedical research, including...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $229,309.00 in funding to The University of Texas M.D. Anderson Cancer Center to examine the role of the NONO pathway in innate immunity against oncolytic adenoviruses. The project aims to advance understanding of how oncolytic viruses can be used to treat brain tumors, as recent clinical trials have shown these therapies can prolong survival for a small percentage of...